Study on the effects of rapamycin and the mTORC1/2 dual inhibitor OSI-027 on the metabolism of colon cancer cells based on UPLC-MS/MS metabolomics [0.03%]
基于UPLC-MS/MS代谢组学的雷帕霉素及其mTORC1/2双靶点抑制剂OSI-027对结肠癌细胞代谢影响的研究
Kai Fan,Yueyuan Wang,Jiangyujing Bian et al.
Kai Fan et al.
mTORC1/2 dual inhibitors may be more effective than mTORC1 inhibitor rapamycin. However, their metabolic impacts on colon cancer cells remain unexplored. We conducted a comparative analysis of the anti-proliferative effects of rapamycin and...
Radiosensitization effect of quinoline-indole-schiff base derivative 10E on non-small cell lung cancer cells in vitro and in tumor xenografts [0.03%]
一种喹啉-吲哚 Schiff 碱衍生物通过体内外实验表现出对非小细胞肺癌的放射增敏作用
Hongwei Liu,Qianqian Wang,Wanying Lan et al.
Hongwei Liu et al.
Radioresistance is an inevitable obstacle in the clinical treatment of inoperable patients with non-small cell lung cancer (NSCLC). Combining treatment with radiosensitizers may improve the efficacy of radiotherapy. Previously, the quinolin...
Ramucirumab for advanced hepatocellular carcinoma in the current real world: a Japanese single-arm study post-REACH-2 (The R-evolution study) [0.03%]
雷西瑅二期临床日本单臂真实世界研究（R-Evolution研究）
Kazufumi Kobayashi,Sadahisa Ogasawara,Ei Itobayashi et al.
Kazufumi Kobayashi et al.
This study aimed to complement the results of the REACH-2 study by prospectively evaluating the safety and efficacy of ramucirumab in advanced hepatocellular carcinoma (HCC) in a real-world setting. This was an open-label, nonrandomized, mu...
A first-in-human phase I trial of daily oral zelenirstat, a N-myristoyltransferase inhibitor, in patients with advanced solid tumors and relapsed/refractory B-cell lymphomas [0.03%]
一项I期人体试验：在晚期实体瘤和复发/难治性B细胞淋巴瘤患者中每日口服N- 我ristat（一种N- 我酰基转移酶抑制剂）的安全性和耐受性
Randeep Sangha,Rahima Jamal,Jennifer Spratlin et al.
Randeep Sangha et al.
Myristoylation, the N-terminal addition of the fatty acid myristate to proteins, regulates membrane-bound signal transduction pathways important in cancer cell biology. This modification is catalyzed by two N-myristoyltransferases, NMT1 and...
177Lu-SN201 nanoparticle shows superior anti-tumor efficacy over conventional cancer drugs in 4T1 orthotopic model [0.03%]
一种新型的放射性标记纳米药物在小鼠原位癌模型中显示出优于传统化疗药的抗肿瘤效果
Sujinna Lekmeechai,Kristian Pietras,Oskar Axelsson
Sujinna Lekmeechai
In the current in-vivo study we demonstrate the potential of the radiolabeled nanoparticle 177Lu-SN201 as an effective anticancer treatment, as evidenced by significantly prolonged survival and reduced tumor burden in the aggressive, triple...
A phase 1/1b, open-label, dose-escalation study of PD-1 inhibitor, cetrelimab alone and in combination with FGFR inhibitor, erdafitinib in Japanese patients with advanced solid tumors [0.03%]
一项在日本晚期实体瘤患者中评估PD-1抑制剂西米利姆单药以及联合FGFR抑制剂厄达塞替尼治疗的I/Ib期开放标签剂量递增研究
Noboru Yamamoto,Yasutoshi Kuboki,Kenichi Harano et al.
Noboru Yamamoto et al.
Immune checkpoint inhibitors are the leading approaches in tumor immunotherapy. The aim of the study was to establish recommended phase 2 doses (RP2Ds) of intravenous cetrelimab, a checkpoint inhibitor, alone and with oral erdafitinib in Ja...
Clinical characteristics, treatment and outcome of pembrolizumab-induced acute pancreatitis [0.03%]
派姆单抗致急性胰腺炎的临床特征、治疗及转归
Panpan Luo,Yuge Guo,Yang He et al.
Panpan Luo et al.
Acute pancreatitis (AP) is a rare adverse event of pembrolizumab with unclear clinical features. This study investigated the clinical features of pembrolizumab-induced AP to provide a reference for prevention and treatment. Case reports, ca...
Lenvatinib rechallenge after failure of lenvatinib and sorafenib in metastatic thyroid cancer [0.03%]
仑伐替尼失败后再次使用仑伐替尼联合索拉非尼治疗转移性甲状腺癌的效果评估
Tomoya Yokota,Satoshi Hamauchi,Takeshi Kawakami et al.
Tomoya Yokota et al.
The oral multikinase inhibitors sorafenib and lenvatinib are currently available as first-line treatment for patients with unresectable or metastatic thyroid cancer. However, treatment options for patients who are refractory to these multik...
John R Cashman,Emily A Cashman
John R Cashman
Worldwide, pancreatic cancer (PC) is a major health problem and almost 0.5 million people were diagnosed with PC in 2020. In the United States, more than 64,000 adults will be diagnosed with PC in 2023. PC is highly resistant to currently a...
A phase 1 study to assess the absolute bioavailability, mass balance, pharmacokinetics, metabolism, and excretion of [14C]-mobocertinib, an oral inhibitor of EGFR exon 20 insertion mutations, in healthy participants [0.03%]
一项评估口服EGFR外显子20插入突变抑制剂莫博赛替尼（mobocertinib）在健康受试者中的绝对生物利用度、物质平衡、药代动力学、代谢和排泄的I期研究
Michael J Hanley,Steven Zhang,Robert Griffin et al.
Michael J Hanley et al.
Mobocertinib (TAK-788) is a first-in-class oral epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor that received accelerated approval for the treatment of patients with non-small cell lung cancer with EGFR exon 20 insertion m...